RADX radiopharmtheranostics.com: ערך חשבונאי למניה

The trend in book value per share for Radiopharm Theranostics (RADX) is illustrated on the GURU.Markets chart, where 1.46 represents the current metric level. This price action reflects the confident scaling of the asset portfolio by experienced management. Growth is driven by partnerships with oncologists and nuclear centers to enable precision therapy. Financially, Radiopharm Theranostics (RADX) is at the pre-revenue stage with high capex, balancing its position through market capital.

For Radiopharm Theranostics (RADX), the key factor for stability remains the capital volume, which is gradually declining due to a lack of revenue and the costs of clinical trials. The trend in final book value per share reflects the remaining equity minus liabilities, allowing investors to assess the business's actual tangible asset base and the risk of falling into a "value trap" as asset liquidity declines.